Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245507 | 0.82 | HTR2A (0.44) | GAAMAPTNPC1RAB9A | |
| SCHEMBL21245518 | 0.81 | ALDH1A1 (0.41) | PPARAMAPTPOLB | |
| SCHEMBL6056303 | 0.78 | PPARG (0.44) | MTNR1AMTNR1BGAAPKMPPARG | |
| SCHEMBL6458546 | 0.77 | ALDH1A1 (0.43) | CYP1A2GAAMAPTPOLBNPC1 | |
| SCHEMBL7582723 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1B | |
| SCHEMBL11129303 | 0.76 | MTNR1A (0.53) | MTNR1AMTNR1BCYP1A2GAACYP2C9 | |
| SCHEMBL4989765 | 0.76 | TAAR1 (0.55) | ALOX5 | |
| SCHEMBL353033 | 0.76 | MTNR1A (0.53) | MTNR1AMTNR1BCYP1A2GAACYP2C9 | |
| SCHEMBL9487296 | 0.76 | MAPK1 (0.58) | PKMPPARGPPARAMAPTRAB9A | |
| SCHEMBL3160069 | 0.75 | MTNR1A (0.50) | MTNR1AMTNR1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-1572188-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004054566-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | MTNR1A 108/4885MTNR1B 107/4885CYP1A2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.